Moore Law PLLC Launches Investigation into Unicycive Therapeutics
Law firm Moore Law PLLC is investigating potential securities violations at Unicycive Therapeutics following the company's receipt of a second FDA rejection.
Moore Law PLLC has initiated an investigation into Unicycive Therapeutics, Inc. (NASDAQ: UNCY) concerning potential securities violations. The legal firm is currently soliciting information from shareholders regarding the company's recent regulatory disclosures.
The investigation stems from a June 30, 2026, announcement in which Unicycive disclosed that the U.S. Food and Drug Administration (FDA) issued a second Complete Response Letter regarding the company’s drug application. Such letters typically indicate that an application cannot be approved in its current form, often requiring additional clinical data or manufacturing changes.
Investors who purchased shares prior to the June 2026 disclosure are encouraged to contact legal counsel to determine if the company or its executives misrepresented the status of the regulatory approval process. The firm is assessing whether the disclosure resulted in a loss of shareholder value caused by allegedly misleading statements.
Legal inquiries remain preliminary, and no formal class-action lawsuit has been filed at this stage. Shareholders seeking to participate in the investigation are advised to contact Moore Law PLLC directly for case-specific evaluations.